HUP9901820A2 - 4-amino pyrimidine derivatives, medicaments containing these compounds, their use and process for their production - Google Patents
4-amino pyrimidine derivatives, medicaments containing these compounds, their use and process for their productionInfo
- Publication number
- HUP9901820A2 HUP9901820A2 HU9901820A HUP9901820A HUP9901820A2 HU P9901820 A2 HUP9901820 A2 HU P9901820A2 HU 9901820 A HU9901820 A HU 9901820A HU P9901820 A HUP9901820 A HU P9901820A HU P9901820 A2 HUP9901820 A2 HU P9901820A2
- Authority
- HU
- Hungary
- Prior art keywords
- crc
- production
- compounds
- pyrimidine derivatives
- medicaments containing
- Prior art date
Links
- 150000005007 4-aminopyrimidines Chemical class 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 abstract 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000003884 phenylalkyl group Chemical group 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A találmány tárgyát az (I) általánős képletű 4-aminő-pirimidin-származékők, taűtőmereik, sztereőizőmereik és sóik (kivéve a 4-[(3-bróm-fenil)-aminő]-6-(1-piperidinil)-piridő([3,4-d]pirimidint) - ahől Ra hidrőgénatőm vagy metilcsőpőrt, Rb szűbsztitűált fenil- vagy fenil-alkil-csőpőrt, A és B együtt egy -N=CRc-CH=CH-, -CH=N-CRc=CH-, -CH=CRc-N=CH-, -CH=CH-CRc=N- vagy -CH=N-CRc=N- általánős képletű hidat képez, amelyben Rc különféleképp szűbsztitűált, nitrőgéntartalmú gyűrű - azelőállításűkra szőlgáló eljárás és a hatóanyagként ezeket tartalmazógyógyszerkészítmények képezik. ŕThe subject of the invention is 4-aminopyrimidine derivatives of general formula (I), their solvates, stereoisomers and salts (except for 4-[(3-bromophenyl)amino]-6-(1-piperidinyl)pyrido([ 3,4-d]pyrimidine) - where Ra is a hydrogen atom or a methyl group, Rb is a substituted phenyl or phenylalkyl group, A and B together form a -N=CRc-CH=CH-, -CH=N-CRc=CH- , -CH=CRc-N=CH-, -CH=CH-CRc=N- or -CH=N-CRc=N- forms a bridge with the general formula, in which Rc is a variously substituted, nitrogen-containing ring - the process for its production and these as the active ingredient medicinal preparations containing ŕ
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE1996108631 DE19608631A1 (en) | 1996-03-06 | 1996-03-06 | New (heterocyclyl- pyrimidino or -pyrido)fused pyrimidine derivatives |
| DE19629652A DE19629652A1 (en) | 1996-03-06 | 1996-07-23 | 4-Amino-pyrimidine derivatives, medicaments containing these compounds, their use and processes for their preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP9901820A2 true HUP9901820A2 (en) | 1999-09-28 |
| HUP9901820A3 HUP9901820A3 (en) | 2001-10-29 |
Family
ID=26023531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU9901820A HUP9901820A3 (en) | 1996-03-06 | 1997-03-03 | 4-amino pyrimidine derivatives, medicaments containing these compounds, their use and process for their production |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP0885226A1 (en) |
| JP (1) | JP2000506847A (en) |
| KR (1) | KR19990087550A (en) |
| CN (1) | CN1212695A (en) |
| AU (1) | AU710274B2 (en) |
| BG (1) | BG102708A (en) |
| BR (1) | BR9708312A (en) |
| CA (1) | CA2243994A1 (en) |
| CZ (1) | CZ281798A3 (en) |
| DE (1) | DE19629652A1 (en) |
| EE (1) | EE9800277A (en) |
| HU (1) | HUP9901820A3 (en) |
| IL (1) | IL125404A0 (en) |
| NO (1) | NO984084D0 (en) |
| NZ (1) | NZ331546A (en) |
| PL (1) | PL328771A1 (en) |
| SK (1) | SK120598A3 (en) |
| TR (1) | TR199801749T2 (en) |
| WO (1) | WO1997032881A1 (en) |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP9901155A3 (en) | 1996-02-13 | 2003-04-28 | Astrazeneca Ab | Quinazoline derivatives as vegf inhibitors |
| KR100489174B1 (en) | 1996-03-05 | 2005-09-30 | 제네카-파마 소시에떼아노님 | 4-anilinoquinazoline derivatives |
| EP1396489A1 (en) * | 1999-01-27 | 2004-03-10 | Pfizer Products Inc. | Heteroaromatic bicyclic derivatives useful as anticancer agents |
| UA71945C2 (en) * | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
| CN100376567C (en) | 1999-11-05 | 2008-03-26 | 阿斯特拉曾尼卡有限公司 | Qinazoline derivs. as VEGF inhibitors |
| JP2009513491A (en) | 2003-06-24 | 2009-04-02 | ノイロサーチ アクティーゼルスカブ | Novel 8-aza-bicyclo [3.2.1] octane derivatives and their use as monoamine neurotransmitter reuptake inhibitors |
| MX2007010068A (en) * | 2005-02-16 | 2007-10-10 | Schering Corp | Piperazine-piperidines with cxcr3 antagonist activity. |
| US8710104B2 (en) | 2008-11-07 | 2014-04-29 | Triact Therapeutics, Inc. | Catecholic butanes and use thereof for cancer therapy |
| JP5697601B2 (en) * | 2008-12-01 | 2015-04-08 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 2,5-Diamino-substituted pyrido [4,3-D] pyrimidines as autotaxin inhibitors against cancer |
| EP2400985A2 (en) | 2009-02-25 | 2012-01-04 | OSI Pharmaceuticals, LLC | Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor |
| EP2400990A2 (en) | 2009-02-26 | 2012-01-04 | OSI Pharmaceuticals, LLC | In situ methods for monitoring the emt status of tumor cells in vivo |
| US8465912B2 (en) | 2009-02-27 | 2013-06-18 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| US8642834B2 (en) | 2009-02-27 | 2014-02-04 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| EP2408479A1 (en) | 2009-03-18 | 2012-01-25 | OSI Pharmaceuticals, LLC | Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor |
| US20120316187A1 (en) | 2009-11-13 | 2012-12-13 | Pangaea Biotech, S.L. | Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer |
| EP2468883A1 (en) | 2010-12-22 | 2012-06-27 | Pangaea Biotech S.L. | Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer |
| US9134297B2 (en) | 2011-01-11 | 2015-09-15 | Icahn School Of Medicine At Mount Sinai | Method and compositions for treating cancer and related methods |
| EP2492688A1 (en) | 2011-02-23 | 2012-08-29 | Pangaea Biotech, S.A. | Molecular biomarkers for predicting response to antitumor treatment in lung cancer |
| WO2012129145A1 (en) | 2011-03-18 | 2012-09-27 | OSI Pharmaceuticals, LLC | Nscle combination therapy |
| EP2702173A1 (en) | 2011-04-25 | 2014-03-05 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
| MX2014002436A (en) | 2011-08-31 | 2014-05-27 | Genentech Inc | Diagnostic markers. |
| JP2014531213A (en) | 2011-09-30 | 2014-11-27 | ジェネンテック， インコーポレイテッド | Diagnostic methylation markers for epithelial or mesenchymal phenotype and response to EGFR kinase inhibitors in tumors or tumor cells |
| WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| WO2013190089A1 (en) | 2012-06-21 | 2013-12-27 | Pangaea Biotech, S.L. | Molecular biomarkers for predicting outcome in lung cancer |
| EP2961412A4 (en) | 2013-02-26 | 2016-11-09 | Triact Therapeutics Inc | Cancer therapy |
| US20160051556A1 (en) | 2013-03-21 | 2016-02-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method and Pharmaceutical Composition for use in the Treatment of Chronic Liver Diseases Associated with a Low Hepcidin Expression |
| US9381246B2 (en) | 2013-09-09 | 2016-07-05 | Triact Therapeutics, Inc. | Cancer therapy |
| US20170027940A1 (en) | 2014-04-10 | 2017-02-02 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
| CN107223163A (en) | 2014-12-24 | 2017-09-29 | 豪夫迈·罗氏有限公司 | For the treatment of bladder cancer, diagnosis and method of prognosis |
| CN110366550A (en) | 2016-12-22 | 2019-10-22 | 美国安进公司 | As the benzisothiazole of the KRAS G12C inhibitor for treating lung cancer, cancer of pancreas or colorectal cancer, isothiazole simultaneously [3,4-b] pyridine, quinazoline, phthalazines, pyrido [2,3-d] pyridazine and pyrido [2,3-d] pyrimidine derivatives |
| JOP20190272A1 (en) | 2017-05-22 | 2019-11-21 | Amgen Inc | Kras g12c inhibitors and methods of using the same |
| AR112797A1 (en) | 2017-09-08 | 2019-12-11 | Amgen Inc | KRAS G12C INHIBITORS AND METHODS OF USING THEM |
| CA3099118A1 (en) | 2018-05-04 | 2019-11-07 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| US11090304B2 (en) | 2018-05-04 | 2021-08-17 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| CA3099045A1 (en) | 2018-05-10 | 2019-11-14 | Amgen Inc. | Kras g12c inhibitors for the treatment of cancer |
| CA3098885A1 (en) | 2018-06-01 | 2019-12-05 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| EP4268898A3 (en) | 2018-06-11 | 2024-01-17 | Amgen Inc. | Kras g12c inhibitors for treating cancer |
| AU2019336588B2 (en) | 2018-06-12 | 2022-07-28 | Amgen Inc. | KRAS G12C inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer |
| CN113194954A (en) | 2018-10-04 | 2021-07-30 | 国家医疗保健研究所 | EGFR inhibitors for the treatment of keratoderma |
| JP2020090482A (en) | 2018-11-16 | 2020-06-11 | アムジエン・インコーポレーテツド | Improved synthesis of key intermediate of kras g12c inhibitor compound |
| AU2019384118A1 (en) | 2018-11-19 | 2021-05-27 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| JP7377679B2 (en) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | Combination therapy comprising a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancer |
| WO2020132648A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Kif18a inhibitors |
| WO2020132651A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Kif18a inhibitors |
| MX2021007158A (en) | 2018-12-20 | 2021-08-16 | Amgen Inc | Heteroaryl amides useful as kif18a inhibitors. |
| JP2022513971A (en) | 2018-12-20 | 2022-02-09 | アムジエン・インコーポレーテツド | Heteroarylamide useful as a KIF18A inhibitor |
| US20230096028A1 (en) | 2019-03-01 | 2023-03-30 | Revolution Medicines, Inc. | Bicyclic heterocyclyl compounds and uses thereof |
| WO2020180768A1 (en) | 2019-03-01 | 2020-09-10 | Revolution Medicines, Inc. | Bicyclic heteroaryl compounds and uses thereof |
| EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
| SG11202112855WA (en) | 2019-05-21 | 2021-12-30 | Amgen Inc | Solid state forms |
| CA3147451A1 (en) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Kif18a inhibitors |
| US20220372018A1 (en) | 2019-08-02 | 2022-11-24 | Amgen Inc. | Kif18a inhibitors |
| JP2022542319A (en) | 2019-08-02 | 2022-09-30 | アムジエン・インコーポレーテツド | KIF18A inhibitor |
| AU2020326627A1 (en) | 2019-08-02 | 2022-03-17 | Amgen Inc. | KIF18A inhibitors |
| CA3155857A1 (en) | 2019-10-24 | 2021-04-29 | Amgen Inc. | Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer |
| WO2021091956A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| JP2022553857A (en) | 2019-11-04 | 2022-12-26 | レボリューション メディシンズ インコーポレイテッド | RAS inhibitor |
| EP4054719A1 (en) | 2019-11-04 | 2022-09-14 | Revolution Medicines, Inc. | Ras inhibitors |
| EP4055017A1 (en) | 2019-11-08 | 2022-09-14 | Revolution Medicines, Inc. | Bicyclic heteroaryl compounds and uses thereof |
| AR120456A1 (en) | 2019-11-14 | 2022-02-16 | Amgen Inc | ENHANCED SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND |
| CA3158188A1 (en) | 2019-11-14 | 2021-05-20 | Amgen Inc. | Improved synthesis of kras g12c inhibitor compound |
| JP2023505100A (en) | 2019-11-27 | 2023-02-08 | レボリューション メディシンズ インコーポレイテッド | Covalent RAS inhibitors and uses thereof |
| CN114929279A (en) | 2020-01-07 | 2022-08-19 | 锐新医药公司 | Methods of administering SHP2 inhibitors and treating cancer |
| WO2021257736A1 (en) | 2020-06-18 | 2021-12-23 | Revolution Medicines, Inc. | Methods for delaying, preventing, and treating acquired resistance to ras inhibitors |
| IL301062A (en) | 2020-09-03 | 2023-05-01 | Revolution Medicines Inc | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| PE20231207A1 (en) | 2020-09-15 | 2023-08-17 | Revolution Medicines Inc | INDOLIC DERIVATIVES AS RAS INHIBITORS IN CANCER TREATMENT |
| CA3203111A1 (en) | 2020-12-22 | 2022-06-30 | Kailiang Wang | Sos1 inhibitors and uses thereof |
| CN117500811A (en) | 2021-05-05 | 2024-02-02 | 锐新医药公司 | Covalent RAS inhibitors and uses thereof |
| WO2022235870A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Ras inhibitors for the treatment of cancer |
| WO2022235864A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Ras inhibitors |
| AR127308A1 (en) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | RAS INHIBITORS |
| WO2023114954A1 (en) | 2021-12-17 | 2023-06-22 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2024081916A1 (en) | 2022-10-14 | 2024-04-18 | Black Diamond Therapeutics, Inc. | Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL112249A (en) * | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| DE4431867A1 (en) * | 1994-09-07 | 1996-03-14 | Thomae Gmbh Dr K | New 4-amino-pyrimido-pyrimidine derivs. |
-
1996
- 1996-07-23 DE DE19629652A patent/DE19629652A1/en not_active Ceased
-
1997
- 1997-03-03 PL PL97328771A patent/PL328771A1/en unknown
- 1997-03-03 WO PCT/EP1997/001057 patent/WO1997032881A1/en not_active Application Discontinuation
- 1997-03-03 AU AU19251/97A patent/AU710274B2/en not_active Ceased
- 1997-03-03 SK SK1205-98A patent/SK120598A3/en unknown
- 1997-03-03 HU HU9901820A patent/HUP9901820A3/en unknown
- 1997-03-03 CN CN97192787A patent/CN1212695A/en active Pending
- 1997-03-03 EP EP97907066A patent/EP0885226A1/en not_active Ceased
- 1997-03-03 NZ NZ331546A patent/NZ331546A/en unknown
- 1997-03-03 JP JP9531444A patent/JP2000506847A/en active Pending
- 1997-03-03 CZ CZ982817A patent/CZ281798A3/en unknown
- 1997-03-03 IL IL12540497A patent/IL125404A0/en unknown
- 1997-03-03 KR KR1019980706987A patent/KR19990087550A/en not_active Application Discontinuation
- 1997-03-03 EE EE9800277A patent/EE9800277A/en unknown
- 1997-03-03 TR TR1998/01749T patent/TR199801749T2/en unknown
- 1997-03-03 BR BR9708312A patent/BR9708312A/en not_active IP Right Cessation
- 1997-03-03 CA CA002243994A patent/CA2243994A1/en not_active Abandoned
-
1998
- 1998-08-20 BG BG102708A patent/BG102708A/en unknown
- 1998-09-04 NO NO984084A patent/NO984084D0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR19990087550A (en) | 1999-12-27 |
| BR9708312A (en) | 1999-08-03 |
| SK120598A3 (en) | 1999-06-11 |
| EP0885226A1 (en) | 1998-12-23 |
| WO1997032881A1 (en) | 1997-09-12 |
| HUP9901820A3 (en) | 2001-10-29 |
| AU1925197A (en) | 1997-09-22 |
| CA2243994A1 (en) | 1997-09-12 |
| EE9800277A (en) | 1999-02-15 |
| NO984084L (en) | 1998-09-04 |
| AU710274B2 (en) | 1999-09-16 |
| NO984084D0 (en) | 1998-09-04 |
| NZ331546A (en) | 2000-03-27 |
| TR199801749T2 (en) | 1998-12-21 |
| CN1212695A (en) | 1999-03-31 |
| IL125404A0 (en) | 1999-03-12 |
| CZ281798A3 (en) | 1999-02-17 |
| DE19629652A1 (en) | 1998-01-29 |
| PL328771A1 (en) | 1999-02-15 |
| JP2000506847A (en) | 2000-06-06 |
| BG102708A (en) | 1999-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP9901820A2 (en) | 4-amino pyrimidine derivatives, medicaments containing these compounds, their use and process for their production | |
| HUP0000562A2 (en) | Fused pyrazole derivatives, process for their preparation, their use and pharmaceutical compositions containing them | |
| DK0657458T3 (en) | Inhibitors of protein kinase-C | |
| HUP0202795A2 (en) | Pyrimidine and pyrazine derivatives, pharmaceutical compositions containing them and their use | |
| DK0958296T3 (en) | Heterocyclic Compounds, Methods of Preparation and Pharmaceutical Preparations Containing Them and Their Use in the Treatment of Diabetes and Related Diseases | |
| HUP0401339A2 (en) | Novel 4-anilinoquinoline-3-carboxamides, process for their preparation and pharmaceutical compositions containing them | |
| HUP0001507A2 (en) | Pyrrolo [2,3-d] pyrimidine derivatives, process for their preparation, their use and pharmaceutical compositions containing them | |
| IL74031A (en) | 6-(4-(n-cyanoguanidino)phenyl)-4,5-dihydro-3(2h)-pyridazinone derivatives,their preparation and pharmaceutical compositions containing them | |
| ES2103479T3 (en) | ANILIDA DERIVATIVES. | |
| NO971470D0 (en) | New pyrimidone derivatives with fungicidal activity | |
| NO306237B1 (en) | Use of xanthine derivatives as antidepressants | |
| IL111959A (en) | N-(polysubstituted pyrimidin-4-yl) benzenesulfonamide derivatives their preparation and pharmaceutical compositions containing them | |
| HUP0102793A2 (en) | Quinazolines for treating brain tumor and medicaments containing them | |
| NO955074L (en) | 1-substituted istain and oxindole derivatives as inhibitors of acetylcholinesterase | |
| NO20060146L (en) | Benzimidazole derivatives, compositions containing them, their preparation and their use | |
| NO20060147L (en) | Benzimidazole derivatives, compositions containing them, their preparation and their use | |
| DK0726893T3 (en) | New 4-piperidinyl-substituted lactams as neurokinone 2 receptor antagonists for the treatment of asthma | |
| HUP0303480A2 (en) | 4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl) pyrazolo-[1,5-a]-1,3,5-triazine derivatives, as crf-antagonists and pharmaceutical compositions containing them | |
| DE69431069T2 (en) | CYCLIC AMID DERIVATIVES AS NEUROKININ A ANTAGONISTS | |
| ATE186301T1 (en) | 4H-PYRIDO-(1,2-A)PYRIMIDINE-4-ONE SUBSTITUTED AT POSITIONS 2 AND 9 | |
| IL117093A0 (en) | Heterocyclic derivatives | |
| DK0733051T3 (en) | Bicyclic heterocyclic compounds as neurokinin A antagonists | |
| HUP0201315A2 (en) | 4-phenyl-pyrimidine derivatives, process for their preparation, their use and pharmaceutical compositions containing them | |
| NO20022123L (en) | Oxoxazole derivatives for use as inhibitors of phosphodiesterase VII | |
| HUP0101469A2 (en) | 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as alpha-adrenoceptor agonists with improved metabolic stability |